Last reviewed · How we verify
ATI-50002 topical solution
ATI-50002 topical solution is a small molecule that targets the Janus kinase (JAK) pathway.
ATI-50002 topical solution is a small molecule that targets the Janus kinase (JAK) pathway. Used for Moderate to severe plaque psoriasis.
At a glance
| Generic name | ATI-50002 topical solution |
|---|---|
| Sponsor | Aclaris Therapeutics, Inc. |
| Drug class | JAK inhibitor |
| Target | JAK |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 2 |
Mechanism of action
The JAK pathway is involved in the regulation of immune responses, and ATI-50002 is thought to modulate this pathway to treat psoriasis. By inhibiting the JAK pathway, ATI-50002 may help reduce inflammation and slow disease progression.
Approved indications
- Moderate to severe plaque psoriasis
Common side effects
- headache
- nausea
- fatigue
Key clinical trials
- A Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution (PHASE2)
- A Study of ATI-50002 Topical Solution for the Treatment of Vitiligo (PHASE2)
- Safety and Pharmacokinetic Study of ATI-50002 in Subjects With Alopecia Universalis (AU) and Alopecia Totalis (AT) (PHASE2)
- A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata (PHASE2)
- Open Label Study of ATI-50002 Topical Solution Administered to Adult Subjects With Eyebrow Loss Due to Alopecia Areata (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ATI-50002 topical solution CI brief — competitive landscape report
- ATI-50002 topical solution updates RSS · CI watch RSS
- Aclaris Therapeutics, Inc. portfolio CI